Cohort 1 included 14 biopsies from ER+/HER2+ or −, luminal B, or luminal-like primary breast tumors that are treatment-naïve and the paired tumor samples after neoadjuvant antiestrogen treatment. Here, ERBB2 is linked to breast neoplasm.